The company's flagship product, EbeGen, is an electro-chemical biosensor that can detect multiple molecular targets simultaneously, including DNAs, RNAs, and mirRNAs. This technology is 10 times more cost-effective than current methods and does not require sequencing or qPCR. ConquerX has also developed a pan-cancer test that uses high-throughput genomic and proteomic profiling technologies, along with proprietary nanotechnology, to differentiate cancerous cells from healthy ones. This test enables oncologists to screen common biomarkers from different types of cancer cells, making the cancer diagnosis process more efficient. Additionally, ConquerX's Ebegen technology leverages microRNAs as biomarkers to detect up to eighteen types of cancer in a single, cost-effective blood test.